Selected research
Industry Research
Pomalidomide Industry Research Report 2026
Market perspective
The global Pomalidomide market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Pomalidomide is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Pomalidomide is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Pomalidomide is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Pomalidomide include Celgene, Chia Tai-Tianqing, Cipla, Dr Reddy's Laboratories, Hanson Pharm, Indiabulls pharmaceutical, Intas Pharmaceuticals, Meidakang Huakang Pharmaceutical and Natco Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Pomalidomide market in terms of revenue (US$ million) and, where applicable, sales volume (k pcs), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k pcs) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Pomalidomide Market by Company
Celgene
Chia Tai-Tianqing
Cipla
Dr Reddy's Laboratories
Hanson Pharm
Indiabulls pharmaceutical
Intas Pharmaceuticals
Meidakang Huakang Pharmaceutical
Natco Pharma
SL PHARM
Glenmark Pharmaceuticals
Qilu Pharmaceutical
Shandong Kongfu Pharmaceutical
Pomalidomide Segment by Type
1mg Tables
2mg Tables
4mg Tables
Pomalidomide Segment by Application
Clinic
Hospital
Drug Center
Others
Pomalidomide Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pomalidomide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pomalidomide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pomalidomide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Pomalidomide manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Pomalidomide by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Pomalidomide in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 1mg Tables
- 2mg Tables
- 4mg Tables
Applications
- Clinic
- Hospital
- Drug Center
- Others
Companies covered
- Celgene
- Chia Tai-Tianqing
- Cipla
- Dr Reddy's Laboratories
- Hanson Pharm
- Indiabulls pharmaceutical
- Intas Pharmaceuticals
- Meidakang Huakang Pharmaceutical
- Natco Pharma
- SL PHARM
- Glenmark Pharmaceuticals
- Qilu Pharmaceutical
- Shandong Kongfu Pharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Pomalidomide Market Size (2021-2032)
- 2.2.2 Global Pomalidomide Sales (2021-2032)
- 2.2.3 Global Pomalidomide Market Average Price (2021-2032)
- 2.3 Pomalidomide by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 1mg Tables
- 2.3.3 2mg Tables
- 2.3.4 4mg Tables
- 2.4 Pomalidomide by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Clinic
- 2.4.3 Hospital
- 2.4.4 Drug Center
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Pomalidomide Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Pomalidomide Sales (k pcs) of Manufacturers (2021-2026)
- 3.3 Global Pomalidomide Revenue of Manufacturers (2021-2026)
- 3.4 Global Pomalidomide Average Price by Manufacturers (2021-2026)
- 3.5 Global Pomalidomide Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Pomalidomide, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Pomalidomide, Product Type & Application
- 3.8 Global Manufacturers of Pomalidomide, Established Date
- 3.9 Global Pomalidomide Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Celgene
- 4.1.1 Celgene Company Information
- 4.1.2 Celgene Business Overview
- 4.1.3 Celgene Pomalidomide Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Celgene Pomalidomide Product Portfolio
- 4.1.5 Celgene Recent Developments
- 4.2 Chia Tai-Tianqing
- 4.2.1 Chia Tai-Tianqing Company Information
- 4.2.2 Chia Tai-Tianqing Business Overview
- 4.2.3 Chia Tai-Tianqing Pomalidomide Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Chia Tai-Tianqing Pomalidomide Product Portfolio
- 4.2.5 Chia Tai-Tianqing Recent Developments
- 4.3 Cipla
- 4.3.1 Cipla Company Information
- 4.3.2 Cipla Business Overview
- 4.3.3 Cipla Pomalidomide Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Cipla Pomalidomide Product Portfolio
- 4.3.5 Cipla Recent Developments
- 4.4 Dr Reddy's Laboratories
- 4.4.1 Dr Reddy's Laboratories Company Information
- 4.4.2 Dr Reddy's Laboratories Business Overview
- 4.4.3 Dr Reddy's Laboratories Pomalidomide Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Dr Reddy's Laboratories Pomalidomide Product Portfolio
- 4.4.5 Dr Reddy's Laboratories Recent Developments
- 4.5 Hanson Pharm
- 4.5.1 Hanson Pharm Company Information
- 4.5.2 Hanson Pharm Business Overview
- 4.5.3 Hanson Pharm Pomalidomide Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Hanson Pharm Pomalidomide Product Portfolio
- 4.5.5 Hanson Pharm Recent Developments
- 4.6 Indiabulls pharmaceutical
- 4.6.1 Indiabulls pharmaceutical Company Information
- 4.6.2 Indiabulls pharmaceutical Business Overview
- 4.6.3 Indiabulls pharmaceutical Pomalidomide Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Indiabulls pharmaceutical Pomalidomide Product Portfolio
- 4.6.5 Indiabulls pharmaceutical Recent Developments
- 4.7 Intas Pharmaceuticals
- 4.7.1 Intas Pharmaceuticals Company Information
- 4.7.2 Intas Pharmaceuticals Business Overview
- 4.7.3 Intas Pharmaceuticals Pomalidomide Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Intas Pharmaceuticals Pomalidomide Product Portfolio
- 4.7.5 Intas Pharmaceuticals Recent Developments
- 4.8 Meidakang Huakang Pharmaceutical
- 4.8.1 Meidakang Huakang Pharmaceutical Company Information
- 4.8.2 Meidakang Huakang Pharmaceutical Business Overview
- 4.8.3 Meidakang Huakang Pharmaceutical Pomalidomide Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Meidakang Huakang Pharmaceutical Pomalidomide Product Portfolio
- 4.8.5 Meidakang Huakang Pharmaceutical Recent Developments
- 4.9 Natco Pharma
- 4.9.1 Natco Pharma Company Information
- 4.9.2 Natco Pharma Business Overview
- 4.9.3 Natco Pharma Pomalidomide Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Natco Pharma Pomalidomide Product Portfolio
- 4.9.5 Natco Pharma Recent Developments
- 4.10 SL PHARM
- 4.10.1 SL PHARM Company Information
- 4.10.2 SL PHARM Business Overview
- 4.10.3 SL PHARM Pomalidomide Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 SL PHARM Pomalidomide Product Portfolio
- 4.10.5 SL PHARM Recent Developments
- 4.11 Glenmark Pharmaceuticals
- 4.11.1 Glenmark Pharmaceuticals Company Information
- 4.11.2 Glenmark Pharmaceuticals Business Overview
- 4.11.3 Glenmark Pharmaceuticals Pomalidomide Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Glenmark Pharmaceuticals Pomalidomide Product Portfolio
- 4.11.5 Glenmark Pharmaceuticals Recent Developments
- 4.12 Qilu Pharmaceutical
- 4.12.1 Qilu Pharmaceutical Company Information
- 4.12.2 Qilu Pharmaceutical Business Overview
- 4.12.3 Qilu Pharmaceutical Pomalidomide Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Qilu Pharmaceutical Pomalidomide Product Portfolio
- 4.12.5 Qilu Pharmaceutical Recent Developments
- 4.13 Shandong Kongfu Pharmaceutical
- 4.13.1 Shandong Kongfu Pharmaceutical Company Information
- 4.13.2 Shandong Kongfu Pharmaceutical Business Overview
- 4.13.3 Shandong Kongfu Pharmaceutical Pomalidomide Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Shandong Kongfu Pharmaceutical Pomalidomide Product Portfolio
- 4.13.5 Shandong Kongfu Pharmaceutical Recent Developments
5 Global Pomalidomide Market Scenario by Region
- 5.1 Global Pomalidomide Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Pomalidomide Sales by Region: 2021-2032
- 5.2.1 Global Pomalidomide Sales by Region: 2021-2026
- 5.2.2 Global Pomalidomide Sales by Region: 2027-2032
- 5.3 Global Pomalidomide Revenue by Region: 2021-2032
- 5.3.1 Global Pomalidomide Revenue by Region: 2021-2026
- 5.3.2 Global Pomalidomide Revenue by Region: 2027-2032
- 5.4 North America Pomalidomide Market Facts & Figures by Country
- 5.4.1 North America Pomalidomide Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Pomalidomide Sales by Country (2021-2032)
- 5.4.3 North America Pomalidomide Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Pomalidomide Market Facts & Figures by Country
- 5.5.1 Europe Pomalidomide Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Pomalidomide Sales by Country (2021-2032)
- 5.5.3 Europe Pomalidomide Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Pomalidomide Market Facts & Figures by Country
- 5.6.1 Asia Pacific Pomalidomide Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Pomalidomide Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Pomalidomide Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Pomalidomide Market Facts & Figures by Country
- 5.7.1 South America Pomalidomide Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Pomalidomide Sales by Country (2021-2032)
- 5.7.3 South America Pomalidomide Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Pomalidomide Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Pomalidomide Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Pomalidomide Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Pomalidomide Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Pomalidomide Sales by Type (2021-2032)
- 6.1.1 Global Pomalidomide Sales by Type (2021-2032) & (k pcs)
- 6.1.2 Global Pomalidomide Sales Market Share by Type (2021-2032)
- 6.2 Global Pomalidomide Revenue by Type (2021-2032)
- 6.2.1 Global Pomalidomide Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Pomalidomide Revenue Market Share by Type (2021-2032)
- 6.3 Global Pomalidomide Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Pomalidomide Sales by Application (2021-2032)
- 7.1.1 Global Pomalidomide Sales by Application (2021-2032) & (k pcs)
- 7.1.2 Global Pomalidomide Sales Market Share by Application (2021-2032)
- 7.2 Global Pomalidomide Revenue by Application (2021-2032)
- 7.2.1 Global Pomalidomide Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Pomalidomide Revenue Market Share by Application (2021-2032)
- 7.3 Global Pomalidomide Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Pomalidomide Value Chain Analysis
- 8.1.1 Pomalidomide Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Pomalidomide Production Mode & Process
- 8.2 Pomalidomide Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Pomalidomide Distributors
- 8.2.3 Pomalidomide Customers
9 Global Pomalidomide Analyzing Market Dynamics
- 9.1 Pomalidomide Industry Trends
- 9.2 Pomalidomide Industry Drivers
- 9.3 Pomalidomide Industry Opportunities and Challenges
- 9.4 Pomalidomide Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst